natgillin/translations-raw huggingface dataset:
Most side effects are mild to moderate but some may be serious and need treatment.
Večina neželenih učinkov je blagih do zmernih, a nekateri so lahko resni in zahtevajo zdravljenje.
Most side effects of Briviact were of mild or moderate severity and were considered manageable.
Večina neželenih učinkov zdravila Briviact je bila blaga ali zmerna ter je bila ocenjena kot obvladljiva.
Most side effects were mild to moderate in intensity.
Neželeni učinki so bili večinoma blagi do zmerni.
Most subjects (95.7%) received a single pre- operative dose to maintain haemostasis during surgery.
Večina oseb (95,7 %) je prejela en sam odmerek pred operacijo za ohranitev hemostaze med kirurškim posegom.
Most subjects (N=1370) had a treatment period of at least 12 weeks and 409 had at least 52 weeks (1 year) of exposure.
Pri večini oseb (N = 1.370) je obdobje zdravljenja trajalo vsaj 12 tednov in 409 oseb je bilo izpostavljenih vsaj 52 tednov (1 leto).
Most subjects had LDH ≤ULN (65%), ECOG performance status of 0 (72%), and visceral disease (73%) at baseline.
Večina preiskovancev je imela ob izhodišču vrednost LDH ≤ ZMN (65 %), stanje zmogljivosti 0 po lestvici ECOG (72 %) in zasevke v visceralnih organih (73 %).
Most subjects were WHO Functional Class I (75/234, 32 %) or II (120/234, 51 %) at baseline; fewer patients were Class III (35/234, 15 %) or IV (1/234,
Večina preiskovancev se je na začetku uvrščala v funkcijski razred I po razvrstitvi SZO (75/234, 32 %) ali razred II (120/234, 51 %); manj bolnikov se je uvrščalo v razred III (35/234, 15 %) ali IV (1/234,
Most tyrosine kinase
Večina inhibitorjev
Most tyrosine kinase inhibitors
Večina inhibitorjev tirozin kinaz
Most undesirable effects associated with Agenerase therapy were mild to moderate in severity, early in onset, and rarely treatment-limiting.
Večina neželenih učinkov, povezanih z zdravljenjem z zdravilom Agenerase, je blagih do zmernih, zgodnjega pojava in le redko zahteva omejitev zdravljenja.
Most users who experience these effects find that they can manage and control them by adjusting their diet.
Večina uporabnikov kapsul, ki je imela neželene učinke, se jih je naučila obvladati s prilagoditvijo prehranjevanja.
Most users who experience these effects find that they can manage and control them by adjusting their diet.
Večina uporabnikov tablet, ki je imela neželene učinke, se jih je naučila obvladati s prilagoditvijo prehranjevanja.
Most viruses isolated from patients failing raltegravir had high-level raltegravir resistance resulting from the appearance of two or more mutations.
Večina virusov, izoliranih pri bolnikih, ki se na zdravljenje z raltegravirjem niso odzvali, je imela visoko stopnjo odpornosti na raltegravir, ki je bila posledica pojava dveh mutacij ali več.
Most were considered to be mild and did not necessitate discontinuation of study treatment.
Večina je bila zmernih in zaradi njih ni bila potrebna prekinitev zdravljenja v študiji.
Most were ocular and of mild severity.
Večinoma so se pojavljali na očesu in bili so blagi.
Most were ocular, mild to moderate, and none were serious.
Večina je bila blagih do zmernih učinkov na oko, noben ni bil resen.
Most will resolve following appropriate treatment or on stopping Keytruda.
Večina izzveni po ustreznem zdravljenju ali prekinitvi uporabe zdravila Keytruda.
Most will resolve following appropriate treatment or on stopping Nivolumab BMS.
Večina učinkov izzveni po ustreznem zdravljenju ali prekinitvi uporabe zdravila Nivolumab BMS.
Most will resolve following appropriate treatment or on stopping Opdivo.
Večina učinkov izzveni po ustreznem zdravljenju ali prekinitvi uporabe zdravila Opdivo.
Most will resolve following appropriate treatment or on stopping Yervoy.
Večina učinkov izzveni po ustreznem zdravljenju ali prekinitvi uporabe zdravila Yervoy.
Mosteller Formula: BSA (m2) =
Telesna površina (m2)
Mothers should be instructed to discontinue breastfeeding during treatment.
Materam je treba naročiti, naj v času zdravljenja prekinejo z dojenjem.
Mother’s milk should be thrown away during the first 24 hours after thrombolytic treatment.
V prvih 24 urah po trombolitičnem zdravljenju je treba materino mleko zavreči.
Motion sickness
kinetoza
Motion sickness
labost zaradi vožnje;
motion sickness
potovalna bolezen
Motion sickness (NB), Ear pain (N), Ear discomfort (N)
slabost zaradi vožnje (NB), bolečina v ušesu (N), neprijeten občutek v ušesu (N)
Motion sickness, Tinnitus
kinetoza, tinitus
Motion sickness, tinnitus
morska bolezen, tinitus
Motion sickness, tinnitus
morska bolezen, zvonjenje v ušesih
Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache*
motorična nevropatija*, izguba zavesti (vključno s sinkopo), omotica*, disgevzija*, letargija, glavobol
motor weakness (most often reported in the setting of symptomatic hyperlacetatemia or lactic acidosis syndrome) liver failure
motorična šibkost (najpogosteje opisana v primeru simptomatske hiperlaktatemije ali sindroma laktacidoze) odpoved jeter
Mottled or irregular pigmentation
Lisasta ali nepravilna pigmentac ija
Mottled peach, capsule shaped tablet, debossed with "93" on one side and “212” on the other side.
Tableta lisasto breskove barve v obliki kapsule, z vgraviranim napisom “93” na eni strani in “212” na drugi strani tablete.
Mottled red to reddish brown, circular shaped (tablets for dogs 2–3.5 kg) or rectangular shaped (tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg, tablets for dogs >15–30 kg and tablets for dogs
Lisasto rdeče do rdečkasto rjave, okrogle (tablete za pse 2–3,5 kg) ali pravokotno oblikovane tablete (tablete za pse >3,5–7,5 kg, tablete za pse >7,5–15 kg, tablete za pse >15–30 kg in tablete za pse
Mottled skin
lisasta koža
Mouse, rat and dog studies have shown that free cytarabine is highly toxic for the haemopoietic system.
Raziskave na miših, podganah in psih so pokazale, da je prosti citarabin zelo toksičen za hematopoetski sistem.
mouth
Pankreatitis11
Mouth and tongue irritation including pain
draženje v ustih in draženje jezika, tudi bolečina
mouth and tongue irritation including pain
neprijeten občutek v ustih in jeziku, tudi bolečine
Mouth haemorrhage
krvavitev v ustih
Mouth irritation
vnetje v ustih,
mouth or skin blisters stomach ache
mehurji na ustih ali koži, bolečine v trebuhu.
Mouth pain
bolečine v ustih
mouth pain or problems
bolečina ali težave v ustih
Mouth pain/irritation, mouth sores/inflammation/dryness, taste disturbances, upset stomach, nausea, vomiting, diarrhoea, constipation, abdominal pain/swelling, loss/decrease of appetite.
bolečine/draženje v ustih, rane/vnetje v ustih/suha usta, motnje okušanja, težave z želodcem, slabost s siljenjem na bruhanje, bruhanje, driska, zaprtje, bolečine/otekanje v trebuhu, izguba ali zmanjšanje teka
mouth problems, including dry or sore mouth sensitive tongue, bleeding gums
težave v ustih, vključno s suhimi ali vnetimi usti, občutljiv jezik, krvaveče dlesni
mouth sores
bolečine v ustih
mouth sores
rane v ustih,
mouth sores
ranice v ustih
Mouth sores
razjede v ustih,
mouth sores (mucosal inflammation)
or v ustih (vnetje sluznice)
Mouth sores and inflammation
rane in vnetje v ustni votlini
mouth sores or ulcerations, inflammation of the stomach and intestine;
bolečine ali razjede v ustih, vnetje želodca in črevesa;
mouth sores,
bolečine v ustih,
mouth sores, vomiting blood, inflamation of the lips, dry lips, coated tongue
razjede v ustih, bruhanje krvi, vnetje ustnic, suha usta, obložen jezik
mouth ulcer
razjede v ustih
mouth ulcer
razjede v ustih,
Mouth ulceration
razjede v ustih
mouth ulceration
razjede v ustih,
Mouth ulceration Dyspepsia
razjede v ustih
Mouth ulceration Pancreatitis
razjede v ustih pankreatitis
Mouth ulceration Tongue discolouration
razjede v ustih obarvanje jezika
Mouth ulceration, constipation, vomiting
razjede v ustih, zaprtje, bruhanje
mouth ulceration, stomach pain
razjeda v ustih, bolečine v trebuhu,
Mouth ulceration, stomatitis ulcerative, stomatitis, aphthous stomatitis, dyspepsia, cheilosis, glossitis, gastroesophogeal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder, stomach discomfort, oral pain
razjede v ustih, ulcerozni stomatitis, stomatitis, aftičen stomatitis, dispepsija, cheiloza, glositis, gastroezofagealni refluks, bolezni danke, bolezni prebavil, zaprtje, mehko blato, zobobol, zobne bolezni, neugodje v trebuhu, bolečine v ustih
Mouth ulceration, stomatitis ulcerative, stomatitis, right upper quadrant pain, dyspepsia, glossitis, gastroesophogeal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder
gastroezofagealni refluks, bolezni rektuma, bolezen prebavil, zaprtje, vodeno blato, zobobol, zobne bolezni
Mouth ulcers
ranice v ustih
Mouth ulcers
razjede ustne sluznice
mouth ulcers
razjede v ustih
Mouth ulcers
razjede v ustih,
Mouth ulcers and cold sores (stomatitis), gastritis (inflammation of the stomach), constipation, dry mouth
razjede in vnetje ustne sluznice (stomatitis), gastritis (vnetje želodca), zaprtost, suha usta
Mouth ulcers or inflammation.
vnetje v ustih ali razjede v ustih,
mouth ulcers, stomach pain
razjeda v ustih, bolečine v trebuhu,
Mouth ulcers, stomatitis and oral mucositis have been observed in patients treated with Afinitor (see section 4.8).
Pri bolnikih, ki so jemali zdravilo Afinitor, so opažali razjede v ustni votlini in vnetje ustne sluznice (glejte poglavje 4.8).
Mouth ulcers, stomatitis and oral mucositis have been observed in patients treated with Votubia (see section 4.8).
Pri bolnikih, ki so jemali zdravilo Votubia, so opažali razjede v ustni votlini in vnetje ustne sluznice (glejte poglavje 4.8).
mouth ulcers, swollen lips (‘cheilitis’), oral thrush
ustne razjede, otekle ustnice (heilitis), ustni oprh,
mouth ulcers, swollen lips (‘“cheilitis”’), oral thrush
ustne razjede, otekle ustnice (heilitis), ustni oprh;
Mouth ulcers.
razjede po ustih,
Mouth, nose or throat: cough; dry mouth; funny taste
Usta, nos in žrelo: kašelj, suha usta, čuden okus
Mouth, nose or throat: hoarseness, dry throat or lips; painful or bleeding gums; sensitive tooth or toothache; tongue swollen, discoloured, or has sores; blistering by the tongue; severe pain when swallowing; chest pain close to the lungs; chest pain worsens when taking a deep breath; uncontrolled salivating; overactive thyroid gland
Usta, nos in žrelo: hripavost, suho žrelo ali ustnice, boleče ali krvaveče dlesni, občutljivost zob ali zobobol, oteklost jezika, spremenjena barva jezika ali razjede na jeziku, mehurji na jeziku, huda bolečina pri požiranju, bolečina v prsnem košu blizu pljuč, bolečina v prsnem košu, ki se poslabša ob globokem vdihu, nekontrolirano slinjenje, prekomerno delovanje ščitnice
Mouth, nose or throat: mouth pain, tooth ache; pain when swallowing; nose bleed, stuffy nose; a change in how things smell; sore and raised patches in the mouth; feeling very thirsty with a dry mouth or dry skin; swelling of the thyroid gland, neck or voicebox; underactive thyroid gland; sores or swelling in the mouth, burning feeling on the tongue; feeling of tension or fullness in the nose, cheeks and behind the eyes - sometimes with a throbbing ache, fever or stuffy nose (sinusitis)
Usta, nos in žrelo: bolečina v ustih, zobobol, bolečina pri požiranju, krvavitev iz nosu, zamašen nos, spremembe voha, boleče in privzdignjene lehe v ustih, občutek velike žeje ter suha usta ali suha koža, oteklost ščitnice, vratu ali glasilk, zmanjšano delovanje ščitnice, bolečnost ali oteklost v ustih, pekoč občutek na jeziku, občutek napetosti in polnosti v nosu, licih in za očmi
Mouth, respiratory and urinary tract infections, painful urination
okužbe ust, dihal ali sečil, bolečine pri uriniranju
Mouthpiece
ustnik
Move any bubbles to the tip of the syringe
Vsi mehurčki naj bodo pri konici brizge
Move bottle and the filled syringe back in starting position.
Postavite steklenico in napolnjeno brizgo nazaj v začetni položaj.
Move the cartridge up and down between positions a and b (see picture B) 10 times so that the glass ball moves from one end of the cartridge to the other.
Injekcijski vložek 10-krat obrnite gor in dol med položajema a in b (glejte sliko B), tako da se steklena kroglica premika z enega konca injekcijskega vložka na drugega.
Move the cartridge up and down between positions a and b and back (see the picture) so that the glass ball moves from one end of the cartridge to the other at least 20 times.
Pred prvo uporabo injekcijski vložek premikajte gor in dol med položajema a in b (glejte sliko), tako da se bo steklena kroglica z enega konca vložka na drugega premaknila vsaj 20-krat.
Move the cartridge up and down between positions a and b and back (see the picture) so that the glass ball moves from one end of the cartridge to the other at least 20 times.
Premikajte injekcijski vložek gor in dol med položajema a in b (glejte sliko), tako da se bo steklena kroglica z enega konca vložka na drugega premaknila vsaj 20-krat.
Move the delivery system with the cartridge inside up and down between a and b (see picture at least 10 times until the liquid appears uniformly white, cloudy and aqueous.
Obrnite injekcijski peresnik z injekcijskim vložkom vsaj 10-krat gor in dol med položajema a in b (glejte sliko B), dokler ni tekočina enakomerno bela, motna in vodna.
Move the hinged safety guard back towards the syringe - as shown in the picture.
Priležni varnostni ščitnik igle premaknite nazaj proti brizgi, kot kaže slika.
Move the pen up and down 20 times between the two positions as shown, so the glass ball moves from one end of the cartridge to the other.
Peresnik 20-krat dvignite in spustite, kot prikazuje slika, da se bo steklena kroglica premikala z enega konca vložka na drugega.
Move the pen up and down between positions A and B and back so that the glass ball moves from one end of the cartridge to the other (picture 1A) at least 20 times.
Injekcijski peresnik premikajte gor in dol med položajema A in B ter nazaj, tako da se steklena kroglica premika z enega konca vložka na drugega (slika 1A).
Move the pen up and down between positions A and B and back so that the glass ball moves from one end of the cartridge to the other (picture 1A) at least 20 times.
Peresnik premikajte gor in dol med položajema A in B, tako da se bo steklena kroglica premikala z enega konca vložka na drugega (slika 1A).
Move the pen up and down between the two positions at least 10 times until the liquid appears uniformly white and cloudy.
Obrnite injekcijski peresnik z injekcijskim vložkom vsaj 10-krat gor in dol med položajema, dokler ni tekočina enakomerno bela in motna.
Move the pen up and down between the two positions at least 10 times until the liquid appears uniformly white and cloudy.
Peresnik dvignite in spustite vsaj 10-krat, dokler tekočina ne postane enakomerno bela in motna.
Move the pen up and down between the two positions at least 10 times until the liquid does appear uniformly white, cloudy and aqueous.
Obrnite injekcijski peresnik z injekcijskim vložkom vsaj 10-krat gor in dol med obema položajema, dokler ni tekočina enakomerno bela, motna in vodna.
Move the ring-stop to the opposite end of the plunger.
Premaknite zaporni obroček na nasprotni konec bata.
Move the ring-stop towards the other end of the plunger for choosing the correct dose based on your veterinarian’s prescription.
Premaknite zaporni obroček proti drugemu koncu bata, da izberete pravilni odmerek, ki ga je predpisal veterinar.
movement and coordination disorders, vertigo, confusion
motnje gibanja in koordinacije, vrtoglavica, zmedenost;
Movement disorder
Gibalne motnje
Movement disorder
Motnje gibanja
movement disorder
motnje pri gibanju;
movement disorder with involuntary muscle spasms or malpositions (dystonia), dreaming excessive.
motnje gibanja z neželenimi mišičnimi krči (distonija), prekomerne sanje.
movement disorder with involuntary muscle spasms or malpositions (dystonia). dreaming excessive.
motnje gibanja z neželenimi mišičnimi krči (distonija), prekomerne sanje.
Movement disorders, paralysis, twitching
motnje gibanja, paraliza, mišični krči, trzanje
Movement disorders, paralysis, twitching
motnje gibanja, paraliza, trzanje
Movement disturbance, slow body movement
motnje gibanja, počasno premikanje telesa,
Moventig 12.5 mg film-coated tablets
Moventig 12,5 mg filmsko obložene tablete
Moventig 12.5 mg film-coated tablets Naloxegol
Moventig 12,5 mg filmsko obložene tablete naloksegol
Moventig 12.5 mg tablets are available in aluminium blisters in pack sizes of 30 or 90 film-coated tablets in non-perforated blisters and 90x1 film-coated tablets in perforated unit dose blisters.
Zdravilo Moventig 12,5 mg tablete je na voljo v aluminijskih pretisnih omotih v pakiranjih s 30 ali 90 filmsko obloženimi tabletami v neperforiranih pretisnih omotih ter kot 90 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek.
Moventig 12.5 mg: a mauve coloured, oval, dimensions 10.5 x 5.5 mm film-coated tablet, marked “nGL” on one side and “12.5” on the other side.
Moventig 12,5 mg: 10,5 x 5,5 mm velike filmsko obložene tablete ovalne oblike in slezenaste barve z oznako "nGL" na eni strani in "12,5" na drugi strani.
Moventig 25 mg film-coated tablets
Moventig 25 mg filmsko obložene tablete
Moventig 25 mg tablets are available in aluminium blisters in pack sizes of 10, 30 or 90 film--coated tablets in non-perforated blisters and 90x1 film-coated tablets in perforated unit dose blisters.
Zdravilo Moventig 25 mg tablete je na voljo v aluminijskih pretisnih omotih v pakiranjih z 10, 30 ali 90 filmsko obloženimi tabletami v neperforiranih pretisnih omotih ter kot 90 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek.
Moventig 25 mg: a mauve coloured, oval, dimensions 13 x 7 mm, film-coated tablet, marked “nGL” on one side and “25” on the other side.
Moventig 25 mg: 13 x 7 mm velike filmsko obložene tablete ovalne oblike in slezenaste barve z oznako "nGL" na eni strani in "25" na drugi strani.
Moventig is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Zdravilo Moventig je indicirano za zdravljenje zaprtosti, povzročene z opioidi (OIC – opioid-induced constipation), pri odraslih bolnikih z nezadostnim odzivom na odvajala.
Moventig should be taken on an empty stomach at least 30 minutes before the first meal of the day or 2 hours after the first meal.
Zdravilo Moventig je treba vzeti na prazen želodec vsaj 30 minut pred prvim dnevnim obrokom ali 2 uri po njem.
Moventig should be taken on an empty stomach at least 30 minutes prior to the first meal of the day or 2 hours after the first meal of the day.
Zdravilo Moventig je treba vzeti na prazen želodec vsaj 30 minut pred prvim dnevnim obrokom ali 2 uri po njem.
Moventig should be used with caution in these patients.
Zdravilo Moventig je treba pri takšnih bolnikih uporabljati previdno.
Moventig with drink
Zdravilo Moventig skupaj s hrano in pijačo
moving spots in vision (floaters)
migajoče pikice (motnjave)
Moxidectin
Moksidectin
Moxidectin [mg/kg bw]
Moksidectin [mg/kg t.m.]
Moxidectin [mg/kg bw]
Moksidektin [mg/kg t.m.]
Moxidectin causes paralysis and death of nematodes and heartworms by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites’ nervous system.
Moksidektin povzroči paralizo in odmrtje nematod in srčnih glist tako, da zmoti prenos signalov med živčnimi celicami (živčni prenos) v živčevju zajedavcev.
Moxidectin interacts with GABA and glutamate- gated chloride channels.
Moksidektin selektivno zavira delovanje inhibicijskega nevrotransmiterja gama amino maslene kisline (GAMK).
Moxidectin interacts with GABA and glutamate-gated chloride channels.
Moksidektin selektivno zavira delovanje inhibicijskega nevrotransmiterja gama amino maslene kisline (GAMK).
Moxidectin is active against larval stages of Dirofilaria immitis (L3, L4) and Dirofilaria repens (L3).
Moksidektin deluje na ličinke Dirofilarie immitis (oblike L3, L4) in Dirofilaria repens (L3).
Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family.
Moksidektin 23-(0-methyloxime)-F28249 alfa je makrociklični lakton druge generacije in spada v skupino milbemicinov.
Moxifloxacin (400 mg) was included as an active internal control.
Za aktiven notranji nadzor so uporabljali moksifloksacin (400 mg).
moxifloxacin and clarithromycin, medicines used to treat bacterial infections.
moksifloksacin in klaritromicin, zdravili za zdravljenje bakterijskih okužb,
moxifloxacin, sparfloxacin (see section 4.4 regarding use with other fluoroquinolones)
moksifloksacin, sparfloksacin (glejte poglavje 4.4 glede uporabe z drugimi fluorokinoloni)
Moxifloxacin^
moksifloksacin^
Moxifloxacine, used to treat bacterial infections.
moksifloksacin, ki se uporablja za zdravljenje bakterijskih okužb,
Mozobil 20 mg/ml solution for injection
Mozobil 20 mg/ml raztopina za injiciranje
Mozobil and G-CSF
Mozobil in G- CSF
Mozobil and G-CSF
Mozobil in G-CSF
Mozobil contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free’.
Zdravilo Mozobil vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni »brez natrija«.
Mozobil contains sodium
Zdravilo Mozobil vsebuje natrij
Mozobil has been compared with placebo (a dummy treatment) in two main studies involving 298 adults with a type of lymphoma called non-Hodgkin’s lymphoma and 302 adults with multiple myeloma.
Zdravilo Mozobil so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, ki sta vključevali 298 odraslih z vrsto limfoma, imenovano nehodgkinov limfom, in 302 odrasla z multiplim mielomom.
Mozobil is a solution for injection that contains the active substance plerixafor.
Zdravilo Mozobil je raztopina za injiciranje, ki vsebuje zdravilno učinkovino pleriksafor.
Mozobil is for subcutaneous injection.
Zdravilo Mozobil se subkutano injicira.
Mozobil is given as an injection under the skin, six to 11 hours before each session when the patient’s blood is taken and the stem cells are extracted.
Zdravilo Mozobil se daje z injiciranjem pod kožo šest do 11 ur pred vsakim odvzemom bolnikove krvi in pridobivanjem matičnih celic.
Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly (see section 4.2).
Zdravilo Mozobil je indicirano v kombinaciji z granulocitne kolonije stimulirajočim faktorjem (G-CSF- granulocyte-colony stimulating factor) za pospeševanje mobilizacije krvotvornih matičnih celic v periferno kri, za zbiranje in kasnejšo avtologno presaditev pri odraslih bolnikih z limfomom in multiplim mielomom, ki imajo nezadostno mobilizacijo celic (glejte poglavje 4.2).
Mozobil is supplied as a clear colourless or pale yellow solution for injection in a glass vial with a non-latex rubber stopper.
Zdravilo Mozobil se dobavi v obliki bistre, brezbarvne ali bledo rumene raztopine za injiciranje v stekleni viali z gumijastim zamaškom, ki ne vsebuje lateksa.
Mozobil is used to help dislodge (‘mobilise’) the stem cells from the bone marrow so they can be released into the blood.
Zdravilo Mozobil se uporablja za pospeševanje odstranitve (mobilizacije) matičnih celic iz kostnega mozga, tako da se lahko sproščajo v kri.
Mozobil is used to help to collect haematopoietic stem cells (cells in the bone marrow that can develop into different types of blood cells) for transplantation.
Zdravilo Mozobil se uporablja za pospeševanje zbiranja krvotvornih matičnih celic (celic v kostnem mozgu, ki se lahko razvijejo v različne vrste krvnih celic) za presaditev.
Mozobil is used together with a hormone called granulocyte colony-stimulating factor (G-CSF).
Zdravilo Mozobil se uporablja skupaj s hormonom, imenovanim granulocitne kolonije stimulirajoči faktor (G-CSF).
Mozobil may cause dizziness and fatigue.
Zdravilo Mozobil lahko povzroči omotico in utrujenost.